Freshfields advises Patient Square Capital and Elevage Medical Technologies on investment in 4basebio PLC

Freshfields advised Patient Square Capital and its Elevage Medical Technologies (‘Elevage’) platform on an investment by Elevage and Prudential Assurance Company Limited (acting by its investment manager M&G Investment Management Limited) (‘M&G’) in 4basebio PLC (AIM: 4BB), an AIM-listed company that develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions.

The investment will consist of a £40.0 million issuance of new shares and the acquisition of £29.4 million of shares from certain existing shareholders. Following completion, Elevage and M&G will together hold 29.9% of 4basebio.

Learn more about this transaction here.

The cross-border Freshfields team was led by private capital partners Ian Bushner, Tamara Young and Charles Hayes and senior associate Olivia Mackay.